Arrowhead Pharmaceuticals (ARWR) FY2017 results: revenue $31 million, up 19736.5% on the year
Arrowhead Pharmaceuticals, Inc. (ARWR) reported revenue of $31 million for fiscal 2017, the year ended 30 September 2017, up 19736.5% on the year before. Net income was -$34 million, and diluted earnings per share $-0.47. The figures are the company's own, from the 10-K it filed with the SEC on 12 December 2017.
Revenue
$31 million
+19,736.5% on the year
FY2011FY2017
Operating margin
-117.8%
-51627.1% a year earlier
FY2011FY2017
Net income
-$34 million
FY2011FY2017
Diluted EPS
-$0.47
FY2011FY2017
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Revenue
31.4
0.2
0.4
+19,736.5%
Research and development
50.9
62.1
47.3
-18.1%
Operating income
-37.0
-81.7
-96.0
Operating margin
-117.8%
-51627.1%
-25124.1%
Pre-tax income
-34.4
-81.7
-91.9
Income tax
0.0
0.0
0.0
0.0%
Net income
-34.4
-81.7
-91.9
Net margin
-109.5%
-51614.6%
-24068.3%
Diluted EPS
-$0.47
-$1.34
-$1.60
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Operating cash flow
-23.9
-64.4
-65.7
Capital expenditure
7.9
3.9
2.0
+105.1%
Free cash flow
-31.9
-68.3
-67.7
Free cash flow margin
-101.4%
-43129.2%
-17716.8%
Cash from investing
-48.6
13.4
n/a
Cash from financing
12.1
55.1
n/a
-78.1%
Depreciation and amortisation
3.0
3.3
2.3
-8.3%
Share-based compensation
7.9
11.6
10.2
-31.9%
Diluted shares, weighted
74m
n/a
n/a
Shares outstanding at period end
75m
70m
60m
+7.2%
Balance sheet
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Shareholders' equity
81.4
95.6
110
-14.8%
Non-controlling interest
-0.6
-0.6
-0.6
Debt
2.3
2.5
0.0
-8.2%
Other liabilities
20.8
30.6
22.6
-32.0%
Total liabilities and equity
104
128
132
-18.8%
Fixed assets
15.5
15.4
4.5
+0.8%
Intangible assets
20.5
22.2
24.8
-7.7%
Securities held for sale or to maturity
40.8
n/a
17.5
Cash and equivalents
24.8
85.4
81.2
-70.9%
Receivables
0.1
0.1
n/a
-9.6%
Other assets
2.4
5.2
4.2
-54.3%
Total assets
104
128
132
-18.8%
10-K for the year ended 30 September 2017, filed 12 December 2017: the filing.